Dr. Fang Wang is currently the Head of Chemical Development at Global Blood Therapeutics. She is responsible for the chemical process development of all small molecule active pharmaceutical ingredients (API) as well as their manufacturing including clinical manufacturing and commercial manufacturing. Dr. Wang provided API leadership in obtaining FDA’s approval of Oxbryta® NDA three months ahead of schedule in 2019. Most recently, Dr. Wang was the President of Clover Crystallization Consulting for more than two years providing strategic consulting and training to various pharmaceutical companies. Prior to consulting, Dr. Wang was the Head of API Crystallization and Engineering at Gilead Sciences for seven years. She provided strategic and cross-functional leadership to API form selection and API crystallization process development for all Gilead’s development programs ranging from pre-IND through NDA stage programs. Dr. Wang was the key contributor who provided strategic leadership for the crystallization development and commercialization for SOVALDI® and HARVONI®. Prior to Gilead, Dr. Wang started her career at Pharmacia/Pfizer after completing her Ph.D. in Chemical Engineering.
Head of Chemical Development at Global Blood Therapeutics